Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
iv Results Number and quality of studiesRCTs comparing GH with placebo or no treatment were included, and because final height data were rarely available in the context of RCTs, lower levels of evidence were included for final height only, using the highest level of evidence available within each condition.A total of 34 publications reporting 32 studies were included in the assessment of clinical effectiveness.Short-term growth and final height outcomes were evaluated along with some body composition and psychological outcomes.The Jadad quality scores of the trials ranged from 1/5 to 4/5.No existing economic evaluations were found, nor were there any studies reporting appropriate measures of quality of life. Summary of benefitsAlthough the quality of evidence proved variable, the studies suggest that GH treatment can increase short-term growth and improve final height.The reported effects of GH on short-term growth should be considered more reliable because the evidence is of higher quality.The effects of GH on final height should be considered with much greater caution because the quality of the studies is generally much poorer.Results suggest that the effects of GH on shortterm growth velocity (at 1 year) can range from no improvement to approximately 1 standard deviation above the normal growth velocity for children of the same age.Final height gains for treated children over untreated children appear to range from approximately 2 to 11 cm (GHD, 8-11 cm; TS, 5 cm; CRF, 3-9 cm; PWS, 10-11 cm; ISS, 2-7 cm). CostsTreatment with GH is expensive.The lifetime incremental cost of treating one child with GH (as opposed to simply monitoring growth) ranges from £43,100-53,400 (for GHD) to £55,500-83,000 (for PWS).These costs, when applied to children aged 8-15 years with the analysed indications in England and Wales, result in total discounted costs of £904 million for complete treatment.The costs for treating children only in the four licensed conditions would be approximately £180 million. Cost per centimetre gainedThe available data suggest that, under base case conditions, the incremental cost per centimetre gained in final height is approximately £6000 for GHD, £16,000-17,400 for TS, £7400-24,100 for CRF, £13,500-27,200 for ISS and possibly in the region of £7030 for PWS (estimated using year 2000 prices).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981
Quality-of-life measures in chronic diseases of childhood
Eiser, C., & Morse, R. (2001) · Health Technology Assessment · doi:10.3310/hta5040 · Cited by 872
Cutfield, W. S., Wilton, P., Bennmarker, H., Albertsson-Wikland, K., Chatelain, P., Ranke, M. B., & Price, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(99)04055-6 · Cited by 318
Boyle, M. H., Furlong, W., Feeny, D., Torrance, G. W., & Hatcher, J. (1995) · Quality of Life Research · doi:10.1007/bf02260864 · Cited by 194
Cited by
Hobart, J., & Cano, S. (2009) · Health Technology Assessment · doi:10.3310/hta13120 · Cited by 621
Jones, J., Shepherd, J., Baxter, L., Gospodarevskaya, E., Hartwell, D., Harris, P., & Price, A. (2009) · Health Technology Assessment · doi:10.3310/hta13350 · Cited by 357
Self-monitoring of blood glucose in type 2 diabetes: systematic review
Clar, C., Barnard, K., Cummins, E., Royle, P., & Waugh, N. (2010) · Health Technology Assessment · doi:10.3310/hta14120 · Cited by 274
Little, P., Turner, S., Rumsby, K., Warner, G., Moore, M., Lowes, J., Smith, H., Hawke, C., Turner, D., Leydon, G., et al. (2009) · Health Technology Assessment · doi:10.3310/hta13190 · Cited by 137
Vitamin K to prevent fractures in older women: systematic review and economic evaluation
Stevenson, M., Lloyd-Jones, M., & Papaioannou, D. (2009) · Health Technology Assessment · doi:10.3310/hta13450 · Cited by 90
Metadata
- Authors
- Bryant, J., Cave, C., Mihaylova, B., Chase, D., McIntyre, L., Gerard, K., & Milne, R.
- Venue
- Health Technology Assessment
- Published
- 2002
- Volume
- 6
- Issue
- 18
- Pages
- 1-168
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2028479357
- Cited by
- 145
- References
- 4
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. https://app.cochat.ai/papers/10.3310/hta6180
- The paper
- Bryant, J., Cave, C., Mihaylova, B., Chase, D., McIntyre, L., Gerard, K., & Milne, R. (2002). Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technology Assessment. https://doi.org/10.3310/hta6180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.